24 Oct Do Antipsychotics Shorten Duration of Delirium in ICU Patients?
MedicalResearch.com Interview with:
Dr. Ely
Photo: Anne Rayner, VU
Eugene Wesley Ely, M.D.
Dr. E. Wesley Ely is a Professor of medicine at Vanderbilt University School of Medicine with subspecialty training in Pulmonary and Critical Care Medicine.
MedicalResearch.com: What is the background for this study?
Response: Critically ill patients are not benefitting from antipsychotic medications that have been used to treat delirium in intensive care units (ICUs) for more than four decades, according to a study released today in the New England Journal of Medicine.
Each year, more than 7 million hospitalized patients in the United States experience delirium, making them disoriented, withdrawn, drowsy or difficult to wake.
The large, multi-site MIND USA (Modifying the INcidence of Delirium) study sought to answer whether typical and atypical antipsychotics — haloperidol or ziprasidone —affected delirium, survival, length of stay or safety.
Researchers screened nearly 21,000 patients at 16 U.S. medical centers. Of the 1,183 patients on mechanical ventilation or in shock, 566 became delirious and were randomized into groups receiving either intravenous haloperidol, ziprasidone or placebo (saline).
MedicalResearch.com: What are the main findings?
Response: “We found, after extensive investigation with medical centers all over the country, that the patients who get these potentially dangerous drugs are not experiencing any improvements whatsoever in delirium, coma, length of stay or survival,” said senior author by E. Wesley Ely, MD, MPH, professor of Medicine at Vanderbilt University School of Medicine, associate director of Research for the VA Geriatric Research Education Clinical Center, and co-director of the CIBS (Critical Illness, Brain dysfunction, and Survivorship) Center at Vanderbilt University Medical Center.
The investigators found no significant difference in duration of delirium or coma among participants on haloperidol or ziprasidone compared to placebo.
Similarly, there were no significant differences among participants on either antipsychotic medication compared to placebo in 30-day and 90-day mortality or time on the ventilator, or in the ICU and hospital.
MedicalResearch.com: What should readers take away from your report?
Response: “Every day, there are many thousands of patients receiving unnecessary antipsychotics in the critical care setting that are bringing risk and cost without benefit with respect to the outcomes measured in this NIA-sponsored MIND-USA study,” Ely said.
MedicalResearch.com: Is there anything else you would like to add?
Response: Ely’s companion ICU Liberation Collaborative investigation, released today by the Society of Critical Care Medicine, details how to streamline the best way to care for critically ill patients in the ICU by using the ABCDEF Bundle.
The study followed 15,000 patients at 70 medical centers across the United States and found that higher performance of the ABCDEF bundle saved lives, reduced length of stay, reduced delirium and coma, hospital readmissions and made patients less likely to be transferred to nursing homes, Ely said.
“In the ICU Liberation Collaborative investigation, we used a safety bundle much like what your airplane pilots use to help you get safely to your destination,” Ely said. “We try and provide the least amount of sedation to keep people safe and comfortable in the ICU while also managing their delirium, involving their families, getting them mobilized and walking around. ICU teams all over the world are working together to create a new culture of critical care for patients and families.”
The MIND USA study was funded by the National Institute on Aging, part of NIH, with grant AG035177. The ICU Liberation Collaborative was funded by the Gordon and Betty Moore Foundation through the Society of Critical Care Medicine (SCCM).
For more information go to www.icudelirium.org
Citation:
Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness
Timothy D. Girard, M.D., M.S.C.I., Matthew C. Exline, M.D., M.P.H., Shannon S. Carson, M.D.Catherine L. Hough, M.D., Peter Rock, M.D., M.B.A., Michelle N. Gong, M.D., Ivor S. Douglas, M.D., Atul Malhotra, M.D., Robert L. Owens, M.D., Daniel J. Feinstein, M.D., Babar Khan,M.B., B.S., Margaret A. Pisani, M.D., M.P.H., for the MIND-USA Investigators*
October 22, 2018
DOI: 10.1056/NEJMoa1808217
[wysija_form id=”3″]
[last-modified]
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on October 24, 2018 by Marie Benz MD FAAD